PedAM
Pediatric Disease Annotations & Medicines
| Disease | thromboembolism |
| Phenotype | C0042373|vascular disease |
| Sentences | 8 |
| PubMedID- 20539909 | Vkas are effective and recommended for the prevention of venous and arterial thromboembolism in cardiovascular disease, but their pharmacodynamics are difficult to predict and the highly variable interindividual and intraindividual response to treatment accounts for the need of continuous monitoring. |
| PubMedID- 23611368 | Background: abundant thrombin generation may be a major reason for subsequent thromboembolic events in patients with cardiovascular disease receiving dual antiplatelet therapy. |
| PubMedID- 21816733 | Cyp2c19 gene polymorphisms do not influence the clinical efficacy of clopidogrel used to prevent thromboembolic events in patients with ischaemic cardiovascular diseases. |
| PubMedID- 25086257 | In univariate analysis, peri-interventional thromboembolism was associated with peripheral vascular disease (p = .010), impaired left ventricular ejection fraction (p = .040), periprocedural bridging with heparin (p = .007), and previous stroke (p = .026). |
| PubMedID- 25606377 | Clinically, the common causes of thrombophilia include stroke, pregnancy complications (for example, miscarriage, intrauterine growth restriction and placental abruption) and venous thromboembolism (vte) leading to cardiovascular diseases and pulmonary embolism (kosar et al., 2011). |
| PubMedID- 25610501 | Five groups are thus defined-group 1: pulmonary arterial hypertension (pah); group 2: ph resulting from left heart disease; group 3: ph resulting from significant hypoxia or lung parenchymal disease; group 4: vascular disease due to chronic thromboembolic disease; and group 5: ph resulting from multifactorial and/or poorly understood mechanisms. |
| PubMedID- 22370770 | Vkas are effective and extensively recommended for the prevention of venous and arterial thromboembolism in cardiovascular disease. |
| PubMedID- 25699039 | Recognized risk factors for ivig-induced thrombosis include male gender; age >60; diabetes; renal insufficiency, dyslipidemia; hypertension; immobility; coronary disease; pre-existing vascular disease, family history of early thromboembolic disease; atrial fibrillation, high-dose and high-speed ivig infusions. |
Page: 1